Continued here:
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria...

See the original post here:
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study

Link:
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced...

Read the original:
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging

Read more:
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in...

Link:
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

Read more:
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Originally posted here:
Mesoblast Corporate Presentation at Investor Conference

Read more from the original source:
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement

More here:
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage

See the original post here:
New data with daridorexant to be presented at SLEEP 2024

Go here to read the rest:
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan

Continued here:
Number of voting rights as of May 31, 2024

See the original post:
Vidac Pharma receives US patent office Notice of Allowance for crucial compounds in its cancer drug candidates

Read the original:
Orion is developing the Finnish life science industry in a unique collaboration project

See more here:
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care

Here is the original post:
Pharming Group to participate in June investor conferences

Here is the original post:
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

Read the rest here:
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

See the article here:
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences